Get Help Now

Contact a Lawyer in
North or South Carolina.


For decades, the prescription blood thinner warfarin (marketed as Coumadin®) was the only drug approved to treat non-valvular atrial fibrillation (AFib). But within the last ten years, the U.S. Food and Drug Administration (FDA) has approved three next-generation anticoagulants to treat patients with aFib—Pradaxa®, Xarelto®, and Eliquis®. While these drugs provide doctors and patients with more treatment choices than ever before, they have been linked to an increased risk of severe injuries.

If you or someone you love took Pradaxa, Xarelto, or Eliquis and suffered from severe bleeding or other serious injuries, Crumley Roberts wants to help. We have more than 25 years of experience fighting for injury victims, and our drug injury lawyers can help protect your rights to compensation. Call our 24/7 legal team at 866-336-4547 or complete our free initial consultation form to get started now.

Xarelto® and Eliquis® Have No Counteracting Drugs

Xarelto and Eliquis, two popular next-generation blood thinners, have no counteracting drugs to stop severe bleeding once it starts. As a result, patients taking the drug may face an increased risk of severe injury or death in certain patients.

Pradaxa® Bleeding Injury Lawsuits

Pradaxa (dabigatran) is a prescription blood-thinning drug used to reduce the risk of stroke in patients suffering from AFib. Approved by the FDA in 2010, Pradaxa has generated more than $1 billion in worldwide sales.

In May 2014, the FDA published a study comparing the health risks of Pradaxa to warfarin. Data from more than 134,000 Medicare patients age 65 and older showed that patients taking Pradaxa faced a higher risk of gastrointestinal bleeding than patients taking warfarin.

Boehringer Ingelheim, Pradaxa’s manufacturer, has already faced thousands of lawsuits on behalf of injury victims and their families. Evidence made public during these legal proceedings shows that the company failed to share data indicating Pradaxa’s fatal bleeding risk may be higher than was thought during the FDA’s approval process. To date, Boehringer Ingelheim has paid more than $650 million to settle Pradaxa bleeding injury lawsuits.

Xarelto® Bleeding Risks

The FDA approved Xarelto (rivaroxaban) in 2011 and sales of the drug have totaled more than $320 million. But research shows that Xarelto:

  • More than triples the risk of major bleeding among patients suffering from Acute Coronary Syndrome
  • Nearly triples the risk of major bleeding among acutely ill patients taking blood thinners to reduce the risk of blood clots
  • Doubles the risk of severe bleeding among patients undergoing hip surgery
  • May increase the risk of stroke or blood clots.

Eliquis® Severe Bleeding Dangers

Approved by the FDA after Pradaxa and Xarelto, Eliquis (apixaban) presents patients with another treatment alternative to warfarin. But like Xarelto, the drug lacks a counteracting drug to stop severe bleeding.

Patients taking Eliquis may face an increased risk of bleeding requiring hospitalization—or even resulting in death. Eliquis may also increase the risk of other side effects, such as:

  • Blood clots
  • Gastrointestinal bleeding
  • Hemorrhagic stroke (brain bleeding)
  • Intracranial bleeding (bleeding in the skull)
  • Get Help With Your Blood Thinner Lawsuit

Get Help With Your Blood Thinner Lawsuit

At Crumley Roberts, we’re here to protect your rights to compensation if you suffered from severe bleeding, stroke, or blood clots after taking a blood-thinning medication. Our drug injury lawyers won’t charge you attorneys fees unless we win money for you, so don’t wait to get help. Call or contact us online to take action today.

Coumadin® and Eliquis® are registered trademarks of Bristol-Myers Squibb Company and are used here only for the purpose of identifying the products in question. Pradaxa® is a registered trademark of Boehringer Ingelheim and is used here only for the purpose of identifying the product in question. Xarelto® is a registered trademark of Bayer AG and is used here only for the purpose of identifying the product in question.

This law firm is not associated with, sponsored by, or affiliated with Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; or the U.S. Food and Drug Administration.

Free Initial Consultation